Ceftazidime-avibactam
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia
Conditions
Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia
Trial Timeline
Jun 15, 2020 → May 7, 2021
NCT ID
NCT04040621About Ceftazidime-avibactam
Ceftazidime-avibactam is a phase 1 stage product being developed by AbbVie for Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia. The current trial status is terminated. This product is registered under clinical trial identifier NCT04040621. Target conditions include Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04040621 | Phase 1 | Terminated |